About
Pricing
FAQs
Providers
Trials
Blog
Login
Get started
Finding studies
Search
Narrow
Order
Status
Recruiting
Not yet recruiting
Active, not recruiting
Enrolling by invitation
Completed
Terminated
Phase
Early phase 1
Phase 1
Phase 1–2
Phase 2
Phase 2–3
Phase 3
Phase 4
No phase
Who can join
Healthy volunteers too
Searching
1–20 of 242
Completed
Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing
In Phase I the sponsor will systematically test conditions for lavage filtration that increase tumor cell fraction without reducing tumor mutation yield.
NCT04823871
·
Graz and 8 others
Active not recruiting
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
This pilot trial studies how well a diabetes prevention program with or without hunger training works in helping to lower breast cancer risk in obese participants.
NCT03546972
·
Houston, Texas
Completed
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and…
NCT02282345
·
Houston, Texas
Completed
Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy
Short Rationale: Risk-reducing salpingo-oophorectomy (RRSO) is a mainstay in preventing ovarian cancer in BRCA1/2 mutation carriers, as ovarian cancer screening is ineffective in…
NCT02372864
·
Groningen
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx)…
NCT06395519
·
Phoenix, Arizona and 13 others
Completed
Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development
To evaluate 1) the extent of patient overestimation of breast cancer development risk in subjects referred to a physician-based high-risk breast clinic; 2) the ability of…
NCT00381927
·
Springfield, Massachusetts
Completed
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)
BRCA1 carriers who are at high risk of developing either a relapse and/or a new cancer growth will be included.
NCT02608346
·
Lyon and 3 others
Recruiting
Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.
NCT03396341
·
Boston, Massachusetts and 6 others
Withdrawn
Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
This research study is looking at breast cancer risk in women who are BRCA1/BRCA2 mutation carriers.
NCT00899145
·
Philadelphia, Pennsylvania
Completed
Management of Women With BRCA1/2 Mutation
The aim of this study is to determine general practitionners' role in management of women with BRCA1/2 mutation.
NCT03211611
·
Montpellier
Not yet recruiting
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
This is a single arm, open-label, non-randomized multi-institution phase II trial of a Fc enhanced CTLA4 antibody, vilastobart, in combination with PD-1 antibody, retifanlimab, in…
NCT07765836
·
Boston, Massachusetts
Recruiting
Combination Therapy in Cancers With Mutations in DNA Repair Genes
The purpose of this phase 1 clinical trials is to determine whether niraparib (a Poly (ADP-ribose) polymerase inhibitor (PARPi)) can be safely combined with irinotecan with…
NCT05694715
·
San Francisco, California
Recruiting
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
In TNBC patients who have completed neoadjuvant immunotherapy and local treatment, a 9-cycle regimen of PD-1 inhibitor adjuvant immunotherapy is currently considered the standard…
NCT06533384
·
Guangzhou, Guangdong
Completed
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a Phase 1, dose escalation trial evaluating the tolerability, pharmacokinetics, and pharmacodynamics of ABT-767 in subjects with advanced Breast Cancer 1 or 2 gene (BRCA1…
NCT01339650
·
Groningen and 2 others
Completed
Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study
This clinical trial evaluates the impact of enhanced risk assessments on knowledge, perceptions, and decisional conflict about cancer prevention in women with a BRCA1 or BRCA2…
NCT06534424
·
Columbus, Ohio and 1 other
Completed
Decision Support for BRCA Testing in Ethnically Diverse Women
The objective of this study is to expand genetic testing for hereditary breast and ovarian cancer syndrome to a broader population of high-risk women by prompting appropriate…
NCT03470402
·
New York, New York
Unknown
The Use of Digital Genetic Counselor (DGC) for BRCA1/2 Mutation Carrier Testing
The DGC provides an end-to-end solution to the Oncogenetics screening process from participant registration to receipt of the genetic test results and their interpretation.
NCT04038905
Active not recruiting
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations.
NCT04367675
·
Philadelphia, Pennsylvania
Completed
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
This phase I trial is studying the side effects and best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with advanced solid cancer.
NCT00535119
·
Duarte, California and 6 others
Completed
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care
The primary goal of this research is to develop and test a web-based genetic education/counseling intervention.
NCT02957981
·
Washington D.C., District of Columbia
Back
1
2
3
···
13
1 / 13
Next
Data from
ClinicalTrials.gov
Terms
